Lyell Immunopharma (LYEL) Total Liabilities (2019 - 2026)

Lyell Immunopharma's Total Liabilities history runs 8 years deep, the most recent figure standing at $77.0 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 17.49% year-over-year to $77.0 million; the TTM figure through Mar 2026 stood at $77.0 million (down 17.49% YoY), while the FY2025 annual figure was $91.8 million, down 14.98% from the prior year.
• Total Liabilities came in at $77.0 million for Q1 2026 at Lyell Immunopharma, down from $91.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $190.9 million in Q1 2022 to a low of $77.0 million in Q1 2026.
• A 5-year average of $105.7 million and a median of $95.1 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities sank 49.37% in 2023 and grew 13.63% in 2024, its largest moves.
• Lyell Immunopharma's Total Liabilities stood at $104.3 million in 2022, then fell by 8.85% to $95.1 million in 2023, then grew by 13.63% to $108.0 million in 2024, then slipped by 14.98% to $91.8 million in 2025, then declined by 16.21% to $77.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $77.0 million, $91.8 million, and $78.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison